On May 19, 2022, The Siga Technologies, Inc. (NASDAQ: SIGA) announced the approval of its intravenous (IV) formulation of TPOXX® (tecovirimat) by the U.S. Food and Drug Administration (FDA). The drug is intended to treat smallpox, and the approval offers a much-needed alternative to those...
Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table. These Companies have major upcoming catalysts such as an impending FDA approval, drug launch,data...
Immunome, Inc. (NASDAQ: IMNM), a biopharmaceutical company developing novel first-in-class antibody therapeutics targeting oncology and infectious diseases, announced the receipt of a clinical hold letter from the U.S. Food and Drug Administration (FDA) for its recently submitted Investigational New Drug (IND) for IMM-BCP-01, a three-antibody...
RegenxBio, Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company which is cementing its place as a global leader in gene therapies, targeting the treatment of retinal, metabolic, and neurodegenerative diseases. The Company is leveraging a proprietary NAV Technology Platform to develop a pipeline of candidates...
